Baxter meets national shortage of Intravenous (IV) Metronidazole

Dear Healthcare Professional,

Shortage of registered medicine AUST R 129476 and 118321 and alternative supply arrangements under Section 19A of the Therapeutic Goods Act.

DBL Metronidazole Intravenous Infusion AUST R 129476 and Metronidazole Sandoz IV AUST R 118321, sponsored by Hospira and Sandoz, respectively, are in short supply due to manufacturing and commercial changes.

Baxter Healthcare Pty Ltd has been able to arrange for supply of an alternative product, Baxter Metronidazole 500mg/100mL Intravenous Infusion, registered and marketed in the NZ on a temporary basis. This product is NOT registered in Australia and supply is authorized under an exemption granted by the Therapeutic Goods Administration (TGA) under section 19A of the Therapeutic Goods Act 1989 until 31 August 2017.

Please note Annex 1 to this letter details the differences between DBL Metronidazole Intravenous Infusion AUST R 129476 and Baxter Metronidazole 500mg/100mL Intravenous Infusion.

Please refer to DBL Metronidazole Intravenous Infusion Australian Product Information for indications, recommended dosing and adverse reaction profile. Patients should be advised to refer to the Australian Consumer Medicines Information available from the Pharmacist or from the TGA website,

Please call Baxter on 1800 229 837 to report adverse events relating to the administration of Baxter Metronidazole 500mg/100mL.

Yours sincerely,
Baxter Healthcare Pty Ltd

Dr Victor Carey

Dr Victor Carey
Medical Director
Baxter Healthcare

If you would like to order Baxter Metronidazole 500mg/100mL Intravenous Infusion please call 1800BAXTER, (1800 229 837)

Please note the code for this product is AHB3399 and the pack factor is 10, 500mg/100mL bags per cartoon, with a minimum order of 1 cartoon.